167 related articles for article (PubMed ID: 11707814)
21. Structure-efficacy relationships of immunostimulatory activity of CpG-containing oligodeoxynucleotides on mouse spleen cells.
Du HY; Xia SY; Song HF; Li N; Shang MM; Zou J; Wang QQ; Ou L; Sun X; Ji AG; Tang ZM
Acta Pharmacol Sin; 2007 Oct; 28(10):1637-44. PubMed ID: 17883951
[TBL] [Abstract][Full Text] [Related]
22. Enhancement of antigen-presenting ability of B lymphoma cells by immunostimulatory CpG-oligonucleotides and anti-CD40 antibody.
Chen W; Yu Y; Shao C; Zhang M; Wang W; Zhang L; Cao X
Immunol Lett; 2001 May; 77(1):17-23. PubMed ID: 11348665
[TBL] [Abstract][Full Text] [Related]
23. Immunomodulation of Japanese encephalitis vaccine through CpG oligodeoxynucleotides in mice.
Sidhapuriwala JN; Sivalingam SP; Lu J; Moochhala SM
Scand J Immunol; 2006 Oct; 64(4):370-5. PubMed ID: 16970676
[TBL] [Abstract][Full Text] [Related]
24. Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs.
Ballas ZK; Krieg AM; Warren T; Rasmussen W; Davis HL; Waldschmidt M; Weiner GJ
J Immunol; 2001 Nov; 167(9):4878-86. PubMed ID: 11673492
[TBL] [Abstract][Full Text] [Related]
25. In vitro and in vivo effects of CpG-Oligodeoxynucleotides (CpG-ODN) on murine transitional cell carcinoma and on the native murine urinary bladder wall.
Olbert PJ; Schrader AJ; Simon C; Dalpke A; Barth P; Hofmann R; Hegele A
Anticancer Res; 2009 Jun; 29(6):2067-76. PubMed ID: 19528466
[TBL] [Abstract][Full Text] [Related]
26. Antimetastatic effect of CpG DNA mediated by type I IFN.
Hafner M; Zawatzky R; Hirtreiter C; Buurman WA; Echtenacher B; Hehlgans T; Männel DN
Cancer Res; 2001 Jul; 61(14):5523-8. PubMed ID: 11454702
[TBL] [Abstract][Full Text] [Related]
27. APC stimulated by CpG oligodeoxynucleotide enhance activation of MHC class I-restricted T cells.
Warren TL; Bhatia SK; Acosta AM; Dahle CE; Ratliff TL; Krieg AM; Weiner GJ
J Immunol; 2000 Dec; 165(11):6244-51. PubMed ID: 11086059
[TBL] [Abstract][Full Text] [Related]
28. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen.
Davis HL; Weeratna R; Waldschmidt TJ; Tygrett L; Schorr J; Krieg AM
J Immunol; 1998 Jan; 160(2):870-6. PubMed ID: 9551923
[TBL] [Abstract][Full Text] [Related]
29. Oligodeoxynucleotides containing unmethylated cytosine-guanine motifs are effective immunostimulants against pneumococcal meningitis in the immunocompetent and neutropenic host.
Ribes S; Zacke L; Nessler S; Saiepour N; Avendaño-Guzmán E; Ballüer M; Hanisch UK; Nau R
J Neuroinflammation; 2021 Feb; 18(1):39. PubMed ID: 33531028
[TBL] [Abstract][Full Text] [Related]
30. Improving the therapeutic index of CpG oligodeoxynucleotides by intralymphatic administration.
von Beust BR; Johansen P; Smith KA; Bot A; Storni T; Kündig TM
Eur J Immunol; 2005 Jun; 35(6):1869-76. PubMed ID: 15909311
[TBL] [Abstract][Full Text] [Related]
31. CpG-containing oligodeoxynucleotides, in combination with conventional adjuvants, enhance the magnitude and change the bias of the immune responses to a herpesvirus glycoprotein.
Ioannou XP; Gomis SM; Karvonen B; Hecker R; Babiuk LA; van Drunen Littel-van den Hurk S
Vaccine; 2002 Nov; 21(1-2):127-37. PubMed ID: 12443671
[TBL] [Abstract][Full Text] [Related]
32. Effective postexposure treatment of retrovirus-induced disease with immunostimulatory DNA containing CpG motifs.
Olbrich AR; Schimmer S; Heeg K; Schepers K; Schumacher TN; Dittmer U
J Virol; 2002 Nov; 76(22):11397-404. PubMed ID: 12388700
[TBL] [Abstract][Full Text] [Related]
33. Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: a role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA.
Jakob T; Walker PS; Krieg AM; Udey MC; Vogel JC
J Immunol; 1998 Sep; 161(6):3042-9. PubMed ID: 9743369
[TBL] [Abstract][Full Text] [Related]
34. CpG ODN can re-direct the Th bias of established Th2 immune responses in adult and young mice.
Weeratna RD; Brazolot Millan CL; McCluskie MJ; Davis HL
FEMS Immunol Med Microbiol; 2001 Dec; 32(1):65-71. PubMed ID: 11750224
[TBL] [Abstract][Full Text] [Related]
35. Intranasal immunization of mice with CpG DNA induces strong systemic and mucosal responses that are influenced by other mucosal adjuvants and antigen distribution.
McCluskie MJ; Weeratna RD; Davis HL
Mol Med; 2000 Oct; 6(10):867-77. PubMed ID: 11126201
[TBL] [Abstract][Full Text] [Related]
36. Protection of neonatal chicks against a lethal challenge of Escherichia coli using DNA containing cytosine-phosphodiester-guanine motifs.
Gomis S; Babiuk L; Allan B; Willson P; Waters E; Ambrose N; Hecker R; Potter A
Avian Dis; 2004 Dec; 48(4):813-22. PubMed ID: 15666862
[TBL] [Abstract][Full Text] [Related]
37. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity.
Chu RS; Targoni OS; Krieg AM; Lehmann PV; Harding CV
J Exp Med; 1997 Nov; 186(10):1623-31. PubMed ID: 9362523
[TBL] [Abstract][Full Text] [Related]
38. Effects of intravenous and subcutaneous administration on the pharmacokinetics, biodistribution, cellular uptake and immunostimulatory activity of CpG ODN encapsulated in liposomal nanoparticles.
Wilson KD; Raney SG; Sekirov L; Chikh G; deJong SD; Cullis PR; Tam YK
Int Immunopharmacol; 2007 Aug; 7(8):1064-75. PubMed ID: 17570323
[TBL] [Abstract][Full Text] [Related]
39. Liposome-encapsulated CpG oligodeoxynucleotides as a potent adjuvant for inducing type 1 innate immunity.
Suzuki Y; Wakita D; Chamoto K; Narita Y; Tsuji T; Takeshima T; Gyobu H; Kawarada Y; Kondo S; Akira S; Katoh H; Ikeda H; Nishimura T
Cancer Res; 2004 Dec; 64(23):8754-60. PubMed ID: 15574787
[TBL] [Abstract][Full Text] [Related]
40. CpG oligonucleotide therapy cures subcutaneous and orthotopic tumors and evokes protective immunity in murine bladder cancer.
Ninalga C; Loskog A; Klevenfeldt M; Essand M; Tötterman TH
J Immunother; 2005; 28(1):20-7. PubMed ID: 15614041
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
